Base de dados : MEDLINE
Pesquisa : C23.888.089 [Categoria DeCS]
Referências encontradas : 1287 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 129 ir para página                         

  1 / 1287 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29231658
[Au] Autor:Frivik JO; Noraas S; Grankvist A; Wennerås C; Quarsten H
[Ti] Título:A man in his sixties from Southern Norway with intermittent fever.
[Ti] Título:En mann i 60-årene fra Sørlandet med intermitterende feber..
[So] Source:Tidsskr Nor Laegeforen;137(23-24), 2017 12 12.
[Is] ISSN:0807-7096
[Cp] País de publicação:Norway
[La] Idioma:eng; nor
[Mh] Termos MeSH primário: Infecções por Anaplasmataceae
Febre/virologia
Doenças Transmitidas por Carrapatos
[Mh] Termos MeSH secundário: Idoso
Anaplasmataceae/isolamento & purificação
Infecções por Anaplasmataceae/complicações
Infecções por Anaplasmataceae/diagnóstico
Infecções por Anaplasmataceae/tratamento farmacológico
Antibacterianos/uso terapêutico
Astenia/virologia
Doxiciclina/uso terapêutico
Seres Humanos
Masculino
Meia-Idade
Noruega
Doenças Transmitidas por Carrapatos/complicações
Doenças Transmitidas por Carrapatos/diagnóstico
Doenças Transmitidas por Carrapatos/tratamento farmacológico
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); N12000U13O (Doxycycline)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE
[do] DOI:10.4045/tidsskr.17.0353


  2 / 1287 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771813
[Au] Autor:Vale Rodrigues R; Santos F; Pereira da Silva J; Francisco I; Claro I; Albuquerque C; Lemos MM; Limbert M; Dias Pereira A
[Ad] Endereço:Serviço de Gastrenterologia, Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Rua Prof. Lima Basto, 1099-023, Lisbon, Portugal. rita.vale.rodrigues@gmail.com.
[Ti] Título:A case of multiple gastrointestinal stromal tumors caused by a germline KIT gene mutation (p.Leu576Pro).
[So] Source:Fam Cancer;16(2):267-270, 2017 04.
[Is] ISSN:1573-7292
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Multiple gastrointestinal stromal tumors (GISTs) caused by germline KIT gene mutations are an extremely rare autosomal dominant disorder. We report a case of a 21-year-old woman who presented to the emergency department with a 2-week history of asthenia, palpitations and upper gastrointestinal bleeding. After further clinical evaluation one gastric and two small bowel GISTs were diagnosed, which were surgically resected after neoadjuvant therapy with Imatinib. Diffuse hyperplasia of the interstitial cells of Cajal was also seen in the background gastric and small intestinal walls. Somatic mutational analysis of the KIT gene revealed a substitution at codon 576 in exon 11 (p.Leu576Pro) in all tumors and normal ileal mucosa. The germline nature of this mutation was confirmed by mutation analysis in peripheral blood leukocytes. However, she had no familial history of GISTs and her parents did not carry the respective germline mutation.
[Mh] Termos MeSH primário: Neoplasias Gastrointestinais/genética
Tumores do Estroma Gastrointestinal/genética
Neoplasias Primárias Múltiplas/genética
Proteínas Proto-Oncogênicas c-kit/genética
Doenças Raras/genética
[Mh] Termos MeSH secundário: Adulto
Antineoplásicos/uso terapêutico
Astenia/etiologia
Biópsia
Análise Mutacional de DNA
Endoscopia Gastrointestinal
Éxons
Feminino
Hemorragia Gastrointestinal/etiologia
Neoplasias Gastrointestinais/complicações
Neoplasias Gastrointestinais/diagnóstico
Neoplasias Gastrointestinais/terapia
Tumores do Estroma Gastrointestinal/complicações
Tumores do Estroma Gastrointestinal/diagnóstico
Tumores do Estroma Gastrointestinal/terapia
Mutação em Linhagem Germinativa
Seres Humanos
Mesilato de Imatinib/uso terapêutico
Células Intersticiais de Cajal/patologia
Intestino Delgado/patologia
Intestino Delgado/cirurgia
Terapia Neoadjuvante
Neoplasias Primárias Múltiplas/complicações
Neoplasias Primárias Múltiplas/diagnóstico
Neoplasias Primárias Múltiplas/terapia
Estômago/patologia
Estômago/cirurgia
Tomografia Computadorizada por Raios X
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 8A1O1M485B (Imatinib Mesylate); EC 2.7.10.1 (Proto-Oncogene Proteins c-kit)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171224
[Lr] Data última revisão:
171224
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1007/s10689-016-9941-1


  3 / 1287 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28389316
[Au] Autor:García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; Del Alba AG; Castellano D; Gallardo E; Anido U; Del Muro XG; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J
[Ad] Endereço:Medical Oncology, HM Hospitales-Centro Integral Oncológico HM Clara Campal, Madrid, Spain.
[Ti] Título:Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
[So] Source:Lancet Oncol;18(5):672-681, 2017 May.
[Is] ISSN:1474-5488
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Maintenance therapy improves outcomes in various tumour types, but cumulative toxic effects limit the choice of drugs. We investigated whether maintenance therapy with vinflunine would delay disease progression in patients with advanced urothelial carcinoma who had achieved disease control with first-line chemotherapy. METHODS: We did a randomised, controlled, open-label, phase 2 trial in 21 Spanish hospitals. Eligible patients had locally advanced, surgically unresectable, or metastatic transitional-cell carcinoma of the urothelial tract, adequate organ function, and disease control after four to six cycles of cisplatin and gemcitabine (carboplatin allowed after cycle four). Patients were randomly assigned (1:1) to receive vinflunine or best supportive care until disease progression. We initially used block randomisation with a block size of six. Four lists were created for the two stratification factors of starting dose of vinflunine and presence of liver metastases. After a protocol amendment, number of cisplatin and gemcitabine cycles was added as a stratification factor, and eight lists were created, still with a block size of six. Finally, we changed to a minimisation procedure to reduce the risk of imbalance between groups. Vinflunine was given every 21 days as a 20 min intravenous infusion at 320 mg/m or at 280 mg/m in patients with an Eastern Cooperative Oncology Group performance status score of 1, age 75 years or older, previous pelvic radiotherapy, or creatinine clearance lower than 60 mL/min. The primary endpoint was median progression-free survival longer than 5·3 months in the vinflunine group, assessed by modified intention to treat. Comparison of progression-free survival between treatment groups was a secondary endpoint. This trial is registered with ClinicalTrials.gov, number NCT01529411. FINDINGS: Between April 12, 2012, and Jan 29, 2015, we enrolled 88 patients, of whom 45 were assigned to receive vinflunine and 43 to receive best supportive care. One patient from the vinflunine group was lost to follow-up immediately after randomisation and was excluded from the analyses. One patient in the best supportive care group became ineligible for the study and did not receive treatment due to a delay in enrolment, but was included in the intention-to-treat efficacy analysis. After a median follow-up of 15·6 months (IQR 8·5-26·0), 29 (66%) of 44 patients in the vinflunine group had disease progression and 24 (55%) had died, compared with 36 (84%) of 43 patients with disease progression and 32 (74%) deaths in the best supportive care group. Median progression-free survival was 6·5 months (95% CI 2·0-11·1) in the vinflunine group and 4·2 months (2·1-6·3) in the best supportive care group (hazard ratio 0·59, 95% CI 0·37-0·96, p=0·031). The most common grade 3 or 4 adverse events were neutropenia (eight [18%] of 44 in the vinflunine group vs none of 42 in the best supportive care group), asthenia or fatigue (seven [16%] vs one [2%]), and constipation (six [14%] vs none). 18 serious adverse events were reported in the vinflunine group and 14 in the best supportive care group. One patient in the vinflunine group died from pneumonia that was deemed to be treatment related. INTERPRETATION: In patients with disease control after first-line chemotherapy, progression-free survival exceeded the acceptable threshold with vinflunine maintenance therapy. Moreover, progression-free survival was longer with vinflunine maintenance therapy than with best supportive care. Vinflunine maintenance had an acceptable safety profile. Further studies of the role of vinflunine are warranted. FUNDING: Pierre-Fabre Médicament.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Carcinoma de Células de Transição/tratamento farmacológico
Quimioterapia de Manutenção
Neoplasias Urológicas/tratamento farmacológico
Vimblastina/análogos & derivados
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antineoplásicos/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Astenia/induzido quimicamente
Carboplatina/administração & dosagem
Carcinoma de Células de Transição/secundário
Cisplatino/administração & dosagem
Constipação Intestinal/induzido quimicamente
Desoxicitidina/administração & dosagem
Desoxicitidina/análogos & derivados
Progressão da Doença
Intervalo Livre de Doença
Fadiga/induzido quimicamente
Feminino
Seguimentos
Seres Humanos
Análise de Intenção de Tratamento
Quimioterapia de Manutenção/efeitos adversos
Masculino
Meia-Idade
Neutropenia/induzido quimicamente
Neoplasias Urológicas/patologia
Vimblastina/efeitos adversos
Vimblastina/uso terapêutico
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0W860991D6 (Deoxycytidine); 5BF646324K (vinflunine); 5V9KLZ54CY (Vinblastine); B76N6SBZ8R (gemcitabine); BG3F62OND5 (Carboplatin); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170810
[Lr] Data última revisão:
170810
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170409
[St] Status:MEDLINE


  4 / 1287 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28295221
[Au] Autor:Berry V; Basson L; Bogart E; Mir O; Blay JY; Italiano A; Bertucci F; Chevreau C; Clisant-Delaine S; Liegl-Antzager B; Tresch-Bruneel E; Wallet J; Taieb S; Decoupigny E; Le Cesne A; Brodowicz T; Penel N
[Ad] Endereço:Medical Oncology Department, Oscar Lambret Center, Lille, France.
[Ti] Título:REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis.
[So] Source:Cancer;123(12):2294-2302, 2017 Jun 15.
[Is] ISSN:1097-0142
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In a placebo-controlled, randomized phase 2 trial (ClinicalTrials.gov identifier NCT01900743), regorafenib improved progression-free survival (PFS) for patients with doxorubicin-pretreated advanced nonadipocytic sarcoma. A quality-adjusted time without symptoms of progression or toxicity (Q-TWiST) post hoc exploratory analysis was applied to provide an integrated measure of its clinical benefit. METHODS: In the base-case analysis, each patient's overall survival (OS) was partitioned into 3 mutually exclusive health states: the time with a grade 3 or 4 adverse event (TOX), the time without symptoms of disease or grade 3 or 4 toxicity from treatment, and the time after tumor progression or relapse. The time spent in each state was weighted with a health-state utility associated with that state and was summed to calculate the Q-TWiST. The stability of the base-case analysis was explored with several sensitivity analyses. RESULTS: In nonadipocytic sarcoma, the PFS was (4.0 months [2.6-5.5 months] with regorafenib vs 1.0 month [0.9-1.8 months] with a placebo; hazard ratio, 0.36 [0.25-0.53]; P < .0001); the OS was 13.4 months (8.6-17.3 months) with regorafenib and 9.0 months (6.8-12.5 months) with a placebo (hazard ratio, 0.67 [0.44-1.02]). With the classic definition of TOX (including all grade 3 and 4 clinical adverse events), the Q-TWiSTs were 8.0 months (7.0-9.0 months) with regorafenib and 5.7 months (4.9-6.4 months) with a placebo (P < .001). CONCLUSIONS: For patients with doxorubicin-pretreated soft-tissue sarcoma, regorafenib significantly improved quality-adjusted survival in comparison with a placebo. Cancer 2017;123:2294-2302. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Compostos de Fenilureia/uso terapêutico
Piridinas/uso terapêutico
Sarcoma/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Alopecia/induzido quimicamente
Anorexia/induzido quimicamente
Astenia/induzido quimicamente
Diarreia/induzido quimicamente
Método Duplo-Cego
Incontinência Fecal/induzido quimicamente
Feminino
Síndrome Mão-Pé/etiologia
Hospitalização
Seres Humanos
Hipertensão/induzido quimicamente
Leiomiossarcoma/tratamento farmacológico
Lipossarcoma/tratamento farmacológico
Masculino
Meia-Idade
Mucosite/induzido quimicamente
Modelos de Riscos Proporcionais
Qualidade de Vida
Sarcoma Sinovial/tratamento farmacológico
Índice de Gravidade de Doença
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Phenylurea Compounds); 0 (Pyridines); 24T2A1DOYB (regorafenib)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170828
[Lr] Data última revisão:
170828
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE
[do] DOI:10.1002/cncr.30661


  5 / 1287 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28282611
[Au] Autor:Massard C; Chi KN; Castellano D; de Bono J; Gravis G; Dirix L; Machiels JP; Mita A; Gonzalez BM; Turri S; Maier J; Csonka D; Chakravartty A; Fizazi K
[Ad] Endereço:Drug Development Department, Gustave Roussy, University of Paris Sud, Villejuif, France; Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: christophe.massard@gustaveroussy.fr.
[Ti] Título:Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
[So] Source:Eur J Cancer;76:36-44, 2017 May.
[Is] ISSN:1879-0852
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) signalling axis and androgen receptor (AR) pathways exhibit reciprocal feedback regulation in phosphatase and tensin homologue (PTEN)-deficient metastatic castration-resistant prostate cancer (CRPC) in preclinical models. This phase Ib study evaluated the pan-PI3K inhibitor buparlisib (BKM120) and the dual pan-PI3K/ mammalian target of rapamycin (mTOR) inhibitor dactolisib (BEZ235) in combination with abiraterone acetate (AA) in patients with CRPC. MATERIALS AND METHODS: Patients with CRPC who had progressed on AA therapy received escalating doses of either buparlisib or dactolisib, along with fixed doses of AA (1000 mg once daily (qd)) and prednisone (5 mg twice daily (bid)). The primary objective was to define the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of either buparlisib or dactolisib in combination with AA. Secondary objectives included safety, antitumour activity (Prostate Cancer Working Group 2 (PCWG2) criteria; 30% of prostate-specific antigen (PSA) decline at ≥week 12) and pharmacokinetic (PK) profile. RESULTS: In buparlisib + AA arm, 25 patients received buparlisib + AA (median age, 67 years; Eastern Cooperative Oncology Group performance status (ECOG PS) of 0/1/2 for 7/17/1 patients, respectively). At 100 mg qd; two patients experienced dose-limiting toxicities (DLTs) (grade 3 hyperglycaemia; grade 2 asthenia), and this was the maximum buparlisib dose explored. Buparlisib + AA showed a 26% lower median area under the curve from time zero to 24°h (AUC ) and 48% lower median maximum serum concentration (Cmax) versus the single-agent buparlisib assessed in first-in-human study. No objective response and few PSA decreases were reported. In dactolisib + AA arm, 18 patients (median age, 71 years; ECOG PS of 0/1 for 6/12 patients, respectively) received dactolisib + AA at the first dose level (200 mg bid). Five patients had 9 DLTs (grades 2&3 stomatitis; grade 3 hyperglycaemia; grades 2& 3 diarrhoea; grades 1& 2 pyrexia, grade 2 vomiting, and grade 2 chills). CONCLUSIONS: Based on the assessment of available pharmacokinetics, safety, and efficacy data, no further study is planned for either buparlisib or dactolisib in combination with AA in CRPC.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Neoplasias de Próstata Resistentes à Castração/tratamento farmacológico
[Mh] Termos MeSH secundário: Acetato de Abiraterona/administração & dosagem
Acetato de Abiraterona/farmacocinética
Idoso
Idoso de 80 Anos ou mais
Aminopiridinas/administração & dosagem
Aminopiridinas/farmacocinética
Protocolos de Quimioterapia Combinada Antineoplásica/farmacocinética
Área Sob a Curva
Astenia/induzido quimicamente
Calafrios/induzido quimicamente
Diarreia/induzido quimicamente
Febre/induzido quimicamente
Seres Humanos
Hiperglicemia/induzido quimicamente
Imidazóis/administração & dosagem
Imidazóis/farmacocinética
Calicreínas/sangue
Masculino
Dose Máxima Tolerável
Meia-Idade
Morfolinas/administração & dosagem
Morfolinas/farmacocinética
Antígeno Prostático Específico/sangue
Neoplasias de Próstata Resistentes à Castração/sangue
Quinolinas/administração & dosagem
Quinolinas/farmacocinética
Estomatite/induzido quimicamente
Vômito/induzido quimicamente
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aminopyridines); 0 (Imidazoles); 0 (Morpholines); 0 (NVP-BKM120); 0 (Quinolines); EC 3.4.21.- (Kallikreins); EC 3.4.21.- (kallikrein-related peptidase 3, human); EC 3.4.21.77 (Prostate-Specific Antigen); EM5OCB9YJ6 (Abiraterone Acetate); RUJ6Z9Y0DT (dactolisib)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170807
[Lr] Data última revisão:
170807
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170311
[St] Status:MEDLINE


  6 / 1287 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28207320
[Au] Autor:Brinkman EL; Weed BC; Patnaik SS; Brazile BL; Centini RM; Wills RW; Olivier B; Sledge DG; Cooley J; Liao J; Rashmir-Raven AM
[Ti] Título:Cardiac findings in Quarter Horses with heritable equine regional dermal asthenia.
[So] Source:J Am Vet Med Assoc;250(5):538-547, 2017 Mar 01.
[Is] ISSN:1943-569X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE To compare biomechanical and histologic features of heart valves and echocardiographic findings between Quarter Horses with and without heritable equine regional dermal asthenia (HERDA). DESIGN Prospective case-control study. ANIMALS 41 Quarter Horses. PROCEDURES Ultimate tensile strength (UTS) of aortic and mitral valve leaflets was assessed by biomechanical testing in 5 horses with HERDA and 5 horses without HERDA (controls). Histologic evaluation of aortic and mitral valves was performed for 6 HERDA-affected and 3 control horses. Echocardiography was performed in 14 HERDA-affected and 11 control horses. Biomechanical data and echocardiographic variables of interest were compared between groups by statistical analyses, RESULTS Mean values for mean and maximum UTS of heart valves were significantly lower in HERDA-affected horses than in controls. Blood vessels were identified in aortic valve leaflets of HERDA-affected but not control horses. Most echocardiographic data did not differ between groups. When the statistical model for echocardiographic measures was controlled for body weight, mean and maximum height and width of the aorta at the valve annulus in short-axis images were significantly associated with HERDA status and were smaller for affected horses. CONCLUSIONS AND CLINICAL RELEVANCE Lower UTS of heart valves in HERDA-affected horses, compared with those of control horses, supported that tissues other than skin with high fibrillar collagen content are abnormal in horses with HERDA. Lack of significant differences in most echocardiographic variables between affected and control horses suggested that echocardiography may not be useful to detect a substantial loss of heart valve tensile strength. Further investigation is warranted to confirm these findings. Studies in horses with HERDA may provide insight into cardiac abnormalities in people with collagen disorders.
[Mh] Termos MeSH primário: Astenia/veterinária
Predisposição Genética para Doença
Cardiopatias/veterinária
Doenças dos Cavalos/etiologia
Dermatopatias/veterinária
[Mh] Termos MeSH secundário: Animais
Astenia/complicações
Estudos de Casos e Controles
Ecocardiografia/veterinária
Feminino
Cardiopatias/complicações
Cardiopatias/diagnóstico
Doenças dos Cavalos/genética
Cavalos
Masculino
Dermatopatias/complicações
Dermatopatias/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170808
[Lr] Data última revisão:
170808
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170217
[St] Status:MEDLINE
[do] DOI:10.2460/javma.250.5.538


  7 / 1287 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28164081
[Au] Autor:Yao Y; Yue M; Wang J; Chen H; Liu M; Zang F; Li J; Zhang Y; Huang P; Yu R
[Ad] Endereço:Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 211166, China.
[Ti] Título:Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.
[So] Source:Can J Gastroenterol Hepatol;2017:8186275, 2017.
[Is] ISSN:2291-2797
[Cp] País de publicação:Egypt
[La] Idioma:eng
[Ab] Resumo:It is urgent for patients with hepatitis C virus (HCV) infection to find a safe, effective, and interferon-free regimen to optimize therapy. A comprehensive analysis was performed to evaluate the efficacy and safety of the grazoprevir combined with elbasvir, with or without ribavirin (RBV), in 777 treatment-naive and treatment-experienced patients with HCV genotype 1 infection from 3 randomized controlled trials (RCTs). We collected data from the following trials: C-WORTHY (NCT01717326), C-SALVAGE (NCT02105454), and C-EDGE (NCT02105467). All patients received grazoprevir plus elbasvir with or without RBV for 12 or 18 weeks. The sustained virological response (SVR) 12 weeks after end of treatment was calculated for overall and subgroups. 568 (73%) patients were treatment-naive. Overall, 95% (95% CI: 93-96) patients achieved SVR12, 95% (95% CI: 92-96) for treatment-naive and 96% (95% CI: 92-98) for previously treated patients, respectively. Treatment duration and treatment regimen did not have great difference in SVR12 rates. The most common AEs were fatigue (18%-29%), headache (20%), nausea (8%-14%), and asthenia (4%-12%). One patient (<1%) receiving grazoprevir plus elbasvir alone and one (<1%) receiving grazoprevir plus elbasvir plus RBV had treatment-related serious AEs. The result shows that 12-week grazoprevir plus elbasvir therapy is safe and effective for treatment-naive patients with HCV genotype 1.
[Mh] Termos MeSH primário: Antivirais/uso terapêutico
Benzofuranos/uso terapêutico
Hepatite C Crônica/tratamento farmacológico
Imidazóis/uso terapêutico
Quinoxalinas/uso terapêutico
[Mh] Termos MeSH secundário: Astenia/induzido quimicamente
Quimioterapia Combinada
Fadiga/induzido quimicamente
Feminino
Genótipo
Cefaleia/induzido quimicamente
Hepacivirus/genética
Seres Humanos
Masculino
Meia-Idade
Náusea/induzido quimicamente
RNA Viral/sangue
Ensaios Clínicos Controlados Aleatórios como Assunto
Ribavirina/uso terapêutico
Resposta Viral Sustentada
Carga Viral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole); 0 (Antiviral Agents); 0 (Benzofurans); 0 (Imidazoles); 0 (Quinoxalines); 0 (RNA, Viral); 49717AWG6K (Ribavirin); 8YE81R1X1J (MK-5172)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170207
[St] Status:MEDLINE
[do] DOI:10.1155/2017/8186275


  8 / 1287 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27951532
[Au] Autor:Milan Manani S; Virzì GM; Gastaldon F; Proglio M; Brocca A; Ronco C
[Ad] Endereço:Department of Nephrology, Dialysis and Transplant, San Bortolo Hospital, Vicenza, Italy.
[Ti] Título:Brief Review and a Clinical Case of Hemolytic Uremic Syndrome Associated with Interferon ß Treatment.
[So] Source:Blood Purif;43(1-3):136-143, 2017.
[Is] ISSN:1421-9735
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:The hemolytic uremic syndrome (HUS) is one of the thrombotic microangiopathies and it consists of the triad of nonimmune microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. The atypical form of HUS (aHUS) is related to causative mutations in complement genes. Some conditions act as a trigger for aHUS in individuals that have a genetic background predisposing to complement activation. Interferon ß is a recombinant-protein therapy approved to treat multiple sclerosis (MS), and can be a causative agent in the occurrence of HUS through anti-angiogenic activity. In this paper, we briefly review aHUS clinical and genetic characteristics. Furthermore, we present a case of a 48-year-old woman, diagnosed with MS and treated with INFß-1b from 2008. In December 2015, she presented with asthenia and loss of muscular strength in the legs and she quickly developed aHUS. Our case suggests that INFß is a possible triggering factor for HUS.
[Mh] Termos MeSH primário: Síndrome Hemolítico-Urêmica/induzido quimicamente
Interferon beta/efeitos adversos
Esclerose Múltipla/complicações
[Mh] Termos MeSH secundário: Astenia
Feminino
Síndrome Hemolítico-Urêmica/etiologia
Seres Humanos
Fatores Imunológicos
Interferon beta/uso terapêutico
Meia-Idade
Esclerose Múltipla/tratamento farmacológico
Força Muscular
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunologic Factors); 77238-31-4 (Interferon-beta)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170316
[Lr] Data última revisão:
170316
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161213
[St] Status:MEDLINE
[do] DOI:10.1159/000454671


  9 / 1287 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27878773
[Au] Autor:Chihaoui M; Chaker F; Yazidi M; Grira W; Ben Amor Z; Rejeb O; Slimane H
[Ad] Endereço:Department of Endocrinology, University of Tunis El Manar, Faculty of Medicine of Tunis, La Rabta Hospital, Tunis, Tunisia. melikachihaoui@yahoo.fr.
[Ti] Título:Ramadan fasting in patients with adrenal insufficiency.
[So] Source:Endocrine;55(1):289-295, 2017 Jan.
[Is] ISSN:1559-0100
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:AIM: The risks of fasting during Ramadan in patients with adrenal insufficiency are unknown. The aims of this study were to evaluate these risks in such patients, to determine the risk factors and finally to set some recommendations. METHODS: It is a cross-sectional study about 180 patients with known and treated adrenal insufficiency. The patients responded to a 14-item questionnaire concerning their knowledge about the disease and fasting during the last month of Ramadan. RESULTS: There were 132 women and 48 men. The mean age was 47.6 ± 15.0 years (14-79). One hundred and thirty eight patients (76.7 %) were advised by their physician not to fast. Ninety-one patients (50.5 %) tried to fast. Complications occurred in 61 cases (67.0 %): asthenia in 88.5 % of cases, intense thirst in 32.8 %, symptoms of dehydration in 49.2 % and symptoms of hypoglycaemia in 18 %. One patient was hospitalized. Fifty-five patients (60.4 %) were able to fast for the whole month. Age, gender, duration of the disease, its primary origin, associated hypothyroidism, diabetes mellitus, hypertension or diabetes insipidus and daily dose of hydrocortisone did not significantly differ between fasters and non-fasters, full-month-fasters and partial-month-fasters, and fasters with complications and fasters without complications. The frequency of adequate knowledge about the disease was significantly higher in full-month-fasters vs. partial-month-fasters, and in fasters without complications vs. those with complications. CONCLUSION: In patients with adrenal insufficiency, fasting can cause complications especially if the level of knowledge about the disease is low.
[Mh] Termos MeSH primário: Insuficiência Adrenal/fisiopatologia
Astenia/fisiopatologia
Jejum/fisiologia
Conhecimentos, Atitudes e Prática em Saúde
Islamismo
Sede/fisiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Estudos Transversais
Feminino
Seres Humanos
Masculino
Meia-Idade
Fatores de Risco
Inquéritos e Questionários
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161124
[St] Status:MEDLINE
[do] DOI:10.1007/s12020-016-1186-0


  10 / 1287 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:28248025
[Au] Autor:Podoinitsyn AA; Dutov VV
[Ad] Endereço:M.F. Vladimirsky Moscow Regional Research Clinical Institute.
[Ti] Título:[Psychological aspects of treating staghorn nephrolithiasis using percutaneous and retrograde nephrolithotripsy].
[So] Source:Urologiia;(5):80-84, 2016 Nov.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: To investigate the level of anxiety and the severity of asthenic state in patients with staghorn nephrolithiasis treated by of minimally invasive therapies - percutaneous nephrolithotripsy (PNLT) and retrograde nephrolithotripsy (RNLT). PATIENTS AND METHODS: This study analyzed the psychological state of 150 patients with staghorn nephrolithiasis aged 25 to 75 years before and after PNLT and RNLT. Testing was performed at baseline, at 5-7 day of hospital stay (average time of preparing for surgery) and after treatment with the use of various questionnaires: Anxiety Scale, Asthenic conditions scale and Pain questionnaire. RESULTS: The follow-up findings shower positive changes, including reduction in the level of anxiety and severity of asthenia in patients of different age groups. The decrease in anxiety level and severity of fatigue was associated with decreased rates of neuropathic component of pain. CONCLUSION: The psychological state of patients with staghorn nephrolithiasis depends on the characteristics of minimally invasive methods of treatment and requires attending physicians and medical personnel to take into consideration the mental and emotional state of patients.
[Mh] Termos MeSH primário: Nefrolitíase/psicologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Ansiedade/psicologia
Astenia/psicologia
Seres Humanos
Litotripsia/métodos
Meia-Idade
Nefrolitíase/terapia
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE



página 1 de 129 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde